PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma

Matsumoto T. , Imagama S. , Ito Z. , Imai R. , Kamada T. , Shimoyama Y. , Matsuyama Y. and Ishiguro N. , Total spondylectomy following carbon ion radiotherapy to treat chordoma of the mobile spine, Bone Joint J 95-B(10) (2013), 1392-1395.

MacMaster M.S. , Goldstein A.M. , Bromley C.M. , Ishibe N. and Parry D.M. , Chordoma: incidence and survival patterns in the United States, 1973-1995, Cancer Causes Control 12(1) (2001), 1-11.

Bergh P. , Kingblom L.G. Gunterberg B. , Remotti F. , Ryd W. and Meis-Kindblom J.M. , Prognostic factors in chordoma of the sacrum and mobile spine. A study of 39 patients, Cancer 88(9) (2000), 2122-2134.

Moojen W.A. , Vleggeert-Lankamp C.L. , Krol A.D. and Dijkstra S.P. , Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable, Spine (Phila Pa 1976) 36(10) (2011), E656-61.

McPherson C.M. , Suki D. , McCutcheon I.E. , Gokaslan Z.L. , Rhines L.D. and Mendel E. , Metastatic disease from spinal chordoma: a 10-year experience, J Neurosurg Spine 5(4) (2006), 277-280.

Ruggieri P. , Angelini A. , Ussia G. , Montalti M. and Mercuri M. , Surgical margins and local control in resection of sacral chordomas, Clin Orthop Relat Res 468(11) (2010), 2939-2947.

Sciubba D.M. , Cheng J.J. , Petteys R.J. , Weber K.L. , Frassica D.A. and Gokaslan Z.L. , Chordoma of the sacrum and vertebral bodies, J Am Acad Orthop Surg 17(11) (2009), 708-717.

Hanna S.A. , Aston W.J. , Briggs T.W. , Cannon S.R. and Saifuddin A. , Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res 466(9) (2008), 2217-2223.

Zaremba T. and Curtin N.J. , PARP inhibitor development for systemic cancer targeting, Anticancer Agents Med Chem 7(5) (2007), 515-523.

Rouleau M. , Patel A. , Hendzel M.J. , Kaufmann S.H. and Poirier G.G. , PARP inhibition: PARP1 and beyond, Nat Rev Cancer 10(4) (2010), 293-301.

Deshmukh D. and Qiu Y. , Role of PARP-1 in prostate cancer, Am J Clin Exp Urol 3(1) (2015), 1-12.

Scheipl S. , Lohberger B. , Rinner B. , Froehlich E.V. , Beham A. , Quehenberger F. , Lazáry A. , Pal Varga P. , Haybaeck J. , Leithner A. and Liegl B. , Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: an immunohistochemical and functional analysis, J Orthop Res 31(12) (2013), 1999-2005.

Yang H. , Zhu L. , Ebraheim N.A. , Liu X. , Castillo S. , Tang T. , Liu J. and Cui H. , Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization, Spine J 9(12) (2009), 972-980.

Chen K. , Mo J. , Zhou M. , Wang G. , Wu G. , Chen H. , Zhang K. and Yang H. , Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis, Med Oncol 31(4) (2014), 886.

Chen K.W. , Yang H.L. , Lu J. , Liu J.Y. and Chen X.Q. , Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients, Spinal Cord 48(2) (2010), 166-171.

Chen K.W. , Yang H.L. , Lu J. , Wang G.L. , Ji Y.M. , Wu G.Z. , Zhu L.F. , Liu J.Y. , Chen X.Q. and Gu Y.P. , Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma, J Neurooncol 101(3) (2011), 357-363.

Rinner B. , Froehlich E.V. , Buerger K. , Knausz H. , Lohberger B. , Scheipl S. , Fischer C. , Leithner A. , Guelly C. , Trajanoski S. , Szuhai K. and Liegl B. , Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1, Int J Oncol 40(2) (2012), 443-451.

Na Z. , Peng B. , Ng S. , Pan S. , Lee J.S. , Shen H.M. and Yao S.Q. , A small-molecule protein-protein interaction inhibitor of PARP1 that targets its BRCT domain, Angew Chem Int Ed Engl 54(8) (2015), 2515-2519.

Xu Z. , Zhang L. , Zhang W. , Meng D. , Zhang H. , Jian Y. , Xu X. , Van Meter M. , Seluanov A. , Gorbunova V. and Mao Z. , SIRT6 rescues the age related decline in base excision repair in a PARP1-dependent manner, Cell Cycle 14(2) (2015), 269-276.

Bao M. , Chen Z. , Xu Y. , Zhao Y. , Zha R. , Huang S. , Liu L. , Chen T. , Li J. , Tu H. and He X. , Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma, Liver Int 32(2) (2012), 331-338.

Veith S. and Mangerich A. , RecQ helicases and PARP1 team up in maintaining genome integrity, Ageing Res Rev 23(Pt A) (2015), 12-28.

Scheil S. , Bruderlein S. , Liehr T. , Starke H. , Herms J. , Schulte M. and Möller P. , Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1, Genes Chromosomes Cancer 32(3) (2001), 203-211.

Akhavan-Sigari R. , Gaab M.R. , Rohde V. , Abili M. and Ostertag H. , Expression of PDGFR-alpha, EGFR and c-MET in spinal chordoma: a series of 52 patients, Anticancer Res 34(2) (2014), 623-630.

Sajish M. and Schimmel P. , A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol, Nature 519(7543) (2015), 370-373.

Green A.R. , Caracappa D. , Benhasouna A.A. , Alshareeda A. , Nolan C.C. , Macmillan R.D. , Madhusudan S. , Ellis I.O. and Rakha E.A. , Biological and clinical significance of PARP1 protein expression in breast cancer, Breast Cancer Res Treat 149(2) (2015), 353-362.

Sabbatino F. , Fusciello C. , Somma D. , Pacelli R. , Poudel R. , Pepin D. , Leonardi A. , Carlomagno C. , Della Vittoria Scarpati G. , Ferrone S. and Pepe S. , Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation, Cytometry A 85(11) (2014), 953-961.

Dziaman T. , Ludwiczak H. , Ciesla J.M. , Banaszkiewicz Z. , Winczura A. , Chmielarczyk M. , Wisniewska E. , Marszalek A. , Tudek B. and Olinski R. , PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1, PLoS One 9(12) (2014), e115558.